Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAR002 in healthy men
NCT07195175Phase 1Recruiting
- Sponsor
- Marea Therapeutics
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MAR002 in acromegaly (6 arms), sponsored by Marea Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 169 days. Started Aug 2025; status: recruiting.
02
Drugs
MAR002
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT07195175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195175.